Bigmar Announces 1999 First Quarter Results.

COLUMBUS, Ohio--(BUSINESS WIRE)--May 18, 1999--

Bigmar, Inc. (Nasdaq SmallCap: BGMR) today reported financial results for the first quarter ended March 31, 1999 (see attached tables).

Net sales for the first quarter ended March 31, 1999 increased to $1,735,311 from $1,436,167 in the same period last year due primarily to increased sales of IV Solutions from the Company's Bioren subsidiary. Sales of Bioren's IV Solutions accounted for approximately 91% of total Company sales, while generic oncology sales were minimal as the Company only commenced production of its 6 new FDA-approved products during the quarter. First quarter 1999 operating expenses decreased approximately 14% over the previous year due to a decrease in personnel costs and activities associated with the completed inspection of the Company's Swiss manufacturing facility by the FDA. The Company reported a smaller net loss for the first quarter of 1999 of $1,775,056, or $0.22 per share (basic), compared to a net loss of $2,115,303, or $0.51 per share (basic), in the first quarter of 1998.

Bigmar recently announced that it commenced its proprietary drug development strategy while continuing to manufacture and market generic oncological products such as calcium leucovorin, methotrexate and cisplatin. In May, the Company signed a licensing and supply agreement with Graminex to develop a new prosatitis therapy, BGM-24, and plans to file an Investigational New Drug Application ("IND") with the Food and Drug Administration ("FDA") for this therapy. While proprietary drug development is now a major part of the overall growth strategy, the Company is continuing to focus on supplying world markets with a full line of generic pharmaceutical products.

John Tramontana of Bigmar, commented, "While we are encouraged to see increased sales from Bioren, the initial production of the FDA-approved generic oncology products at the Company's Swiss plant positions Bigmar to increase revenues substantially in coming quarters. To date, we have been successful in attracting new customers for the products and plant production has gone well."

Mr. Tramontana added, "The development of BGM-24 for prostatitis is a key product opportunity for Bigmar as the market to treat prostatitis is approximately $1.5 billion worldwide. Bigmar is in the fortunate position of having multiple revenue sources such as generic drug sales and Bioren IV solution sales while we pursue proprietary drug development opportunities."

BIGMAR, Inc.'s strategy is to supply world markets with a full line of high-quality, affordably-priced pharmaceutical products focusing on oncology. With distribution rights to more than 20 generic oncological products and six products approved by the FDA, the Company manufactures, in its state-of-the-art facilities in Switzerland, and market through pharmaceutical company partners in Europe and the United States off-patent generic oncological drugs and additional oncological drugs as their patents expire.

Forward-looking statements involve known and unknown risks, uncertainties and other factors as detailed in the Company's SEC reports and filings, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements. -0-

                     BIGMAR, INC. AND SUBSIDIARIES
            CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
                              (unaudited)

                                       Three Months Ended March 31,
                                          1999           1998

Net Sales                             $ 1,735,311    $ 1,436,167
Cost of goods sold                      1,242,128      1,078,442
                                      -----------    -----------
Gross margin                              493,183        357,725
                                      -----------    -----------

Total operating expenses                1,672,808      1,942,983
                                      -----------    -----------

Operating income (loss)                (1,179,625)    (1,585,258)

Other expenses, net                      (595,431)      (530,045)
                                      -----------    -----------

Net income (loss)                     $(1,775,056)   $(2,115,303)
                                      ===========    ===========

Basic (loss) per share                $     (0.22)   $     (0.51)
                                      ===========    ===========

Weighted average shares outstanding     8,175,000      4,185,000